Sydney Lupkin

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.

President Trump’s latest executive order on drug prices aims to lower them by bringing them into line with what other developed countries pay. Experts caution that this is no small task.

The action is intended to build upon the existing program for Medicare drug price negotiations, which was created by the Inflation Reduction Act that passed during the Biden administration.

Large-scale compounding facilities have to stop making tirzepatide, the main ingredient in blockbuster obesity drug Zepbound, Wednesday.

Patients who bought stockpiles of alternative GLP-1 drugs online aren’t sure what to do with them after learning that the compounding pharmacy that made them didn’t have the right license.

The Biden administration is looking to extend Medicare and Medicaid coverage to include obesity drugs like Wegovy and Zepbound. Weight loss drugs are now excluded from mandatory coverage.

The Biden Administration has proposed a rule to require private health insurance to cover over-the-counter birth control pills, spermicide, condoms and plan B.

A survey of employers finds that only about a fifth of large companies cover drugs like Wegovy for weight loss. A majority of companies that do cover the medicines have requirements.

Drug manufacturers have declared obesity drugs to be “available,” but patients are still struggling to fill prescriptions.

Some drugmakers are getting into the telehealth business in a move that might allow them to sell drugs directly to patients.